Influenza Update

JANUARY 18, 2018
Overview

• Update on influenza-like-illness (ILI)

• Update on IHS influenza vaccine coverage

• 2017 – 2018 NSSC vaccine and antiviral supply
Influenza activity increased sharply in the U.S.

The proportion of outpatient visits for influenza-like illness (ILI) was 5.8%, which is above the national baseline of 2.2%.

The most frequently identified influenza virus type reported by public health laboratories during week 52 was influenza A(H3).

13 influenza-associated pediatric deaths in the U.S., for the 2017-2018 season has been reported to CDC.
CDC Health Alert Network Health Advisory
Seasonal Influenza A (H3N2) Activity and Antiviral Treatment of Patients with Influenza

• Remind clinicians that influenza should be high on their list of possible diagnoses for ill patients because influenza activity is increasing nationwide, and

• Advise clinicians that all hospitalized patients and all high-risk patients (either hospitalized or outpatient) with suspected influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral.

• While antiviral drugs work best when treatment is started within 2 days of illness onset, clinical benefit has been observed even when treatment is initiated later.

Link to HAN: https://emergency.cdc.gov/han/index.asp
Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2017-2018 and Selected Previous Seasons
Pneumonia and Influenza Mortality from
the National Center for Health Statistics Mortality Surveillance System

Data through the week ending December 16, 2017, as of January 4, 2017
U.S. Influenza Vaccine Supply

- Influenza vaccine supply:
  - Projected: 151 to 166 million doses

- Distributed doses as of December 15, 2017
  - ~ 150.3 million doses
CDC Vaccine Coverage

Based on estimates as of November 2017:

- 38.6% All (6 months and older)
- 38.8% Children (6 months – 17 years)
- 38.5% Adults (18 years and older)
- 35.6% Pregnant women
- 67.6% Health Care Personnel (HCP)

Data source: FluVaxView: [https://www.cdc.gov/flu/fluvoxview/index.htm](https://www.cdc.gov/flu/fluvoxview/index.htm)
IHS Influenza Like Illness

WEEK 01
IHS Influenza Awareness System as of 1/06/2018 (Week 01)

- Influenza-like-illness (ILI) activity in IHS is elevated at 3.5%, above the IHS baseline of 1.67%
- Eleven IHS regions are reporting elevated ILI activity
- IHS has administered over 285,000 doses of influenza vaccine
- Weekly IIAS reports available on the IHS Flu Website
  - [www.ihs.gov/flu](http://www.ihs.gov/flu)
IHS ILI Activity as of 1/06/18
% of outpatient visits for influenza-like-illness (ILI)
Percentage of ILI Visits per week
All IHS Areas
01/04/09 to 1/06/18
Percent of visits for ILI as of 1/06/18
IHS Influenza Vaccine Coverage

WEEK 01
## Influenza Vaccination Coverage by Age Group*

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Active Clinical Population**</th>
<th>Seasonal Flu Vaccine (At Least 1 Dose)***</th>
<th>% Seasonal Flu (At Least 1 Dose)</th>
<th>Total #Doses Administered****</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 5 months</td>
<td>4,229</td>
<td>38</td>
<td>0.9</td>
<td>38</td>
</tr>
<tr>
<td>6 - 23 months</td>
<td>20,442</td>
<td>9,299</td>
<td>45.5</td>
<td>11,026</td>
</tr>
<tr>
<td>2 - 4 years</td>
<td>51,270</td>
<td>13,169</td>
<td>25.7</td>
<td>13,455</td>
</tr>
<tr>
<td>5 - 17 years</td>
<td>195,712</td>
<td>58,007</td>
<td>29.6</td>
<td>58,421</td>
</tr>
<tr>
<td>18 - 49 years</td>
<td>400,549</td>
<td>91,554</td>
<td>22.9</td>
<td>92,250</td>
</tr>
<tr>
<td>50 - 64 years</td>
<td>169,238</td>
<td>62,925</td>
<td>37.2</td>
<td>63,413</td>
</tr>
<tr>
<td>65 + years</td>
<td>100,837</td>
<td>46,814</td>
<td>46.4</td>
<td>47,376</td>
</tr>
<tr>
<td>Children (6 months-17 years)</td>
<td>267,424</td>
<td>80,475</td>
<td>30.1</td>
<td>82,902</td>
</tr>
<tr>
<td>Adults (18 + years)</td>
<td>670,624</td>
<td>201,293</td>
<td>30.0</td>
<td>203,039</td>
</tr>
<tr>
<td>All (6 months +)</td>
<td>938,048</td>
<td>281,768</td>
<td>30.0</td>
<td>285,941</td>
</tr>
</tbody>
</table>

** Active Clinical is defined as patients who have had at least 2 visits in the last 3 years.  
*** Number of unique patients with at least 1 dose.  
**** Total # Doses Administered = All doses administered to patients including doses not included in coverage calculation due to lack of Active Clinical Population data.
Influenza Vaccine Coverage as of 1/06/2018
Influenza Vaccine Coverage
All (6 months and over)
2016-2017 vs. 2017-2018
# Influenza Vaccine Doses Administered by Influenza Vaccine Type*

<table>
<thead>
<tr>
<th>Area</th>
<th>Inactive CVX Codes*</th>
<th>CVX 88 FLU-NOS**</th>
<th>CVX 135 FLU-HIGH</th>
<th>CVX 140 FLU-IIV3pf</th>
<th>CVX 141 FLU-IIV3</th>
<th>CVX 149 FLU-LAIV4</th>
<th>CVX 150 FLU-IIV4pf</th>
<th>CVX 155 FLU-RIV3</th>
<th>CVX 158 FLU-IIV4</th>
<th>CVX 161 FLU-IIV4pf ped</th>
<th>CVX 166 FLU-DERM4</th>
<th>CVX 168 FLU-IIV3ad</th>
<th>CVX 171 FLU-ccl4pf</th>
<th>CVX 185 FLU-RIV4</th>
<th>CVX 186 FLU-ccl4</th>
<th>Proc 99.52 Vac Inf</th>
<th>ICD-9 V04.81 Vac Inf</th>
<th>CPT Billing Codes+</th>
<th>Cumulative # of Doses Seasonal Flu</th>
</tr>
</thead>
<tbody>
<tr>
<td>AK</td>
<td>1</td>
<td>26</td>
<td>360</td>
<td>3</td>
<td>82</td>
<td>0</td>
<td>4,251</td>
<td>0</td>
<td>1,075</td>
<td>410</td>
<td>2</td>
<td>0</td>
<td>45</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>34</td>
</tr>
<tr>
<td>ALB</td>
<td>0</td>
<td>181</td>
<td>1,773</td>
<td>39</td>
<td>1,028</td>
<td>0</td>
<td>10,638</td>
<td>16</td>
<td>7,717</td>
<td>847</td>
<td>977</td>
<td>1</td>
<td>9</td>
<td>46</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>59</td>
<td>23,337</td>
</tr>
<tr>
<td>BEM</td>
<td>1</td>
<td>101</td>
<td>372</td>
<td>5</td>
<td>354</td>
<td>0</td>
<td>4,076</td>
<td>1</td>
<td>4,411</td>
<td>224</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>35</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>45</td>
<td>9,637</td>
</tr>
<tr>
<td>BIL</td>
<td>0</td>
<td>63</td>
<td>1,379</td>
<td>4</td>
<td>129</td>
<td>0</td>
<td>9,964</td>
<td>4</td>
<td>2,389</td>
<td>309</td>
<td>126</td>
<td>0</td>
<td>132</td>
<td>257</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>81</td>
<td>14,838</td>
</tr>
<tr>
<td>CAO</td>
<td>3</td>
<td>363</td>
<td>1,608</td>
<td>55</td>
<td>1,323</td>
<td>0</td>
<td>6,501</td>
<td>1</td>
<td>3,966</td>
<td>352</td>
<td>68</td>
<td>0</td>
<td>619</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>173</td>
<td>15,032</td>
</tr>
<tr>
<td>GPA</td>
<td>1</td>
<td>310</td>
<td>1,460</td>
<td>5</td>
<td>1,130</td>
<td>1</td>
<td>15,755</td>
<td>5</td>
<td>9,218</td>
<td>1,596</td>
<td>3</td>
<td>3</td>
<td>155</td>
<td>22</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>92</td>
<td>29,763</td>
</tr>
<tr>
<td>NSA</td>
<td>1</td>
<td>115</td>
<td>339</td>
<td>19</td>
<td>367</td>
<td>0</td>
<td>4,329</td>
<td>4</td>
<td>5,167</td>
<td>294</td>
<td>435</td>
<td>1</td>
<td>81</td>
<td>15</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>183</td>
<td>11,353</td>
</tr>
<tr>
<td>NAV</td>
<td>7</td>
<td>254</td>
<td>1,970</td>
<td>14</td>
<td>1,478</td>
<td>1</td>
<td>23,883</td>
<td>9</td>
<td>41,872</td>
<td>1,929</td>
<td>622</td>
<td>0</td>
<td>15</td>
<td>52</td>
<td>17</td>
<td>0</td>
<td>0</td>
<td>142</td>
<td>72,265</td>
</tr>
<tr>
<td>OKC</td>
<td>6</td>
<td>1,683</td>
<td>3,084</td>
<td>5</td>
<td>2,147</td>
<td>2</td>
<td>10,121</td>
<td>11</td>
<td>21,151</td>
<td>2,142</td>
<td>432</td>
<td>0</td>
<td>1,707</td>
<td>16</td>
<td>32</td>
<td>0</td>
<td>0</td>
<td>67</td>
<td>42,606</td>
</tr>
<tr>
<td>PHX</td>
<td>0</td>
<td>769</td>
<td>1,686</td>
<td>2</td>
<td>409</td>
<td>0</td>
<td>18,745</td>
<td>12</td>
<td>11,513</td>
<td>541</td>
<td>4</td>
<td>2</td>
<td>11</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>113</td>
<td>33,813</td>
</tr>
<tr>
<td>POR</td>
<td>5</td>
<td>264</td>
<td>1,443</td>
<td>292</td>
<td>420</td>
<td>0</td>
<td>7,219</td>
<td>20</td>
<td>8,079</td>
<td>547</td>
<td>879</td>
<td>66</td>
<td>904</td>
<td>247</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>159</td>
<td>20,556</td>
</tr>
<tr>
<td>TUC</td>
<td>0</td>
<td>28</td>
<td>30</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>6,734</td>
<td>0</td>
<td>78</td>
<td>29</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>34</td>
</tr>
<tr>
<td>25</td>
<td>4,157</td>
<td>15,504</td>
<td>461</td>
<td>8,868</td>
<td>4</td>
<td>122,216</td>
<td>83</td>
<td>116,636</td>
<td>9,220</td>
<td>3,554</td>
<td>73</td>
<td>3,684</td>
<td>696</td>
<td>78</td>
<td>0</td>
<td>0</td>
<td>1,182</td>
<td>286,441</td>
<td></td>
</tr>
</tbody>
</table>

* Inactive CVX Codes 15 (FLU-TIVhx), 16 (FLU-WHOLE), 111 (FLU-LAIV3), 123 (FLU-H5N1), 144 (FLU-DERMAL), 153 (FLU-NasNOS), and 160 (H5N1,adj) should not be used to document flu vaccines given this flu season.

** CVX Code 88 (FLU-NOS) should only be used to document flu vaccines given elsewhere when flu vaccine type is unknown.

† CPT Flu codes include: 90654-90658, 90662, 90672, 90673, 90685, 90686, G0008, and G8108.

^ ICD9 codes V04.8 and V06.6 are not displayed on this report and are not used in any of the influenza vaccine coverage calculations.
Summary

• Influenza-like illness is continuing to increase
  • Nearly all areas are experiencing elevated ILI activity

• IHS has administered over 285,000 doses of influenza vaccine
  • NOTE: Change in coverage data

• Weekly IIAS reports available on the IHS Flu Website
  • www.ihs.gov/flu
2017-2018
Seasonal Influenza Vaccine and Antiviral Procurement

IHS National Supply Service Center
Pharmacy Support Branch
CDR James J. Cummings, PharmD
James.Cummings@ihs.gov
## 2017-2018 Delivery Timelines

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dosage Form</th>
<th>Delivery timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Afluria® MDVs</strong></td>
<td>Multi-Dose Vial (MDV) -10 doses/vial</td>
<td>50% by Sept. 15&lt;sup&gt;th&lt;/sup&gt;, rest by Oct. 15&lt;sup&gt;th&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Peds/Adult by Seqirus</td>
<td></td>
</tr>
<tr>
<td><strong>Fluzone® 6-35 months</strong></td>
<td>PFS - 0.25mL - 10 doses/package</td>
<td>40% by Aug. 15&lt;sup&gt;th&lt;/sup&gt;, rest by Nov. 11&lt;sup&gt;th&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Pediatric (6-35 months) by Sanofi</td>
<td></td>
</tr>
<tr>
<td><strong>Fluarix® 3 years &amp; older</strong></td>
<td>PFS – 0.5mL – 10 doses/package</td>
<td>50% by Sept. 15&lt;sup&gt;th&lt;/sup&gt;, rest by Oct. 15&lt;sup&gt;th&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Peds/Adult (3 years &amp; older) by GSK</td>
<td></td>
</tr>
<tr>
<td><strong>Fluzone® High Dose</strong></td>
<td>PFS – High Dose - 10 doses/package</td>
<td>50% by Sept. 15&lt;sup&gt;th&lt;/sup&gt;, rest by Oct. 15&lt;sup&gt;th&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>by Sanofi</td>
<td></td>
</tr>
</tbody>
</table>

**Other Vaccines not under a delivery contract**
Flu Vaccine Ordering
Post-Solicitation

Contact “Gabe” Wyatt  aaron.wyatt@ihs.gov
  ◦ He will forward a Flu 413 Form for ordering

Submit Seasonal Flu Form 413 to NSSC
  ◦ NSSC may have stock of additional contract vaccine
    ▪ If not NSSC will contact manufacturers to obtain and if authorized, will purchase additional vaccine. If contract vaccine not available NSSC will contact additional vendors to find best price

Occasionally, FSS priced vaccine available through McKesson but no guarantees
Antiviral Ordering & Procurement

**Tamiflu® 75mg Capsules** may purchase from NSSC at substantially reduced prices by contacting “Gabe” Wyatt (Aaron.Wyatt@ihs.gov) and he will forward a 413 form.

Sign & Complete 413 and fax to “Gabe” (405) 951-6054 or e-mail. E-mail works much better 🌟

- Other dosage forms & strengths available thru McKesson
- NOT Reimbursable thru Insurance (POS)
- Relenza® available thru McKesson Connect
Influenza Antiviral

Tamiflu® Capsules, 75mg, BT/10 priced at $19.24 per bottle – Expires June 2019 (part of the Shelf Life Extension Program (SLEP) for on hand Please contact NSSC for purchasing

NSSC can ship overnight delivery if needed the next day. Typically, we ship 2-3 day ground.